Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Analysts at Piper Sandler issued their Q3 2020 earnings per share estimates for shares of Harmony Biosciences in a research note issued on Sunday, September 13th. Piper Sandler analyst D. Amsellem anticipates that the company will post earnings of ($0.12) per share for the quarter. Piper Sandler currently has a “Overweight” rating and a $61.00 target price on the stock. Piper Sandler also issued estimates for Harmony Biosciences’ Q4 2020 earnings at ($0.09) EPS, Q1 2021 earnings at $0.01 EPS, Q2 2021 earnings at $0.20 EPS, Q3 2021 earnings at $0.39 EPS, Q4 2021 earnings at $0.50 EPS, FY2021 earnings at $1.11 EPS, Q1 2022 earnings at $0.61 EPS, Q2 2022 earnings at $0.75 EPS, FY2022 earnings at $3.00 EPS, FY2023 earnings at $3.90 EPS and FY2024 earnings at $4.37 EPS.
Other analysts have also issued research reports about the stock. Goldman Sachs Group initiated coverage on shares of Harmony Biosciences in a research note on Sunday. They issued a “neutral” rating and a $43.00 price target for the company. Jefferies Financial Group assumed coverage on shares of Harmony Biosciences in a research note on Monday. They issued a “buy” rating and a $51.00 price target for the company.
In other Harmony Biosciences news, Director Jack Nielsen bought 3,057 shares of the stock in a transaction on Monday, August 24th. The stock was purchased at an average price of $34.30 per share, for a total transaction of $104,855.10. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Holdings A/S Novo bought 132,503 shares of the stock in a transaction on Friday, August 21st. The shares were acquired at an average price of $24.00 per share, with a total value of $3,180,072.00. Following the purchase, the insider now owns 4,277,300 shares of the company’s stock, valued at $102,655,200. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 138,296 shares of company stock valued at $3,380,687.
Harmony Biosciences Company Profile
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc was formerly known as Harmony Biosciences II, Inc and changed its name to Harmony Biosciences Holdings, Inc in February 2020.
Further Reading: Cost of Capital Explained
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.